Africa

Asia Pacific

Europe

Middle East

North America

Latin America / Caribbean

South America

test

AbbViePro Logo 2023
MENU
Log in
or
Register
Log in
or
Register
logo
PRESCRIBING INFORMATION
PIVOTAL DATA
PIVOTAL DATA

With OZURDEX® you can achieve real world vision gains for your DME naïve pseudophakic patients

Mean vision gains in a 2018 literature review of 6,842 eyes treated with anti-VEGFs and 1,703 eyes treated with OZURDEX® (n=8,545):

img
img
Our therapy areas
Immunology
Oncology
Neurology
Virology
Our therapy areas
Immunology
Oncology
Neurology
Virology
Additional info
Privacy Policy
Terms and Conditions
Manage Cookies
Contact Us
Additional info
Privacy Policy
Terms and Conditions
Manage Cookies
Contact Us
This website is intended for Healthcare Professionals

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

This website is intended for Italy Healthcare Professionals

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

Date of Preparation: December 2018  |   Approval code AT-ABBV-210058 Aug 21    |    Copyright © 2018 AbbVie Inc. North Chicago, Illinois, U.S.A.

Date of Preparation: December 2018 

Approval code AT-ABBV-210058 Aug 21

Copyright © 2018 AbbVie Inc. North Chicago, Illinois, U.S.A.